UK antitrust regulators have kicked off an inquiry into whether they should approve exchange giant CME Group’s £3.9 billion (US$5.4 billion) purchase of Michael Spencer’s NEX Group. The Competition and Markets Authority (CMA) stated on Thursday, September 13, that it is considering whether the acquisition, agreed upon in March, could result in a “substantial lessening” of competition within the UK.
The filing kicks off a 40 business-day timetable in which the CMA must approve the deal, or send it for an in-depth investigation. Then agency must make a decision by November 8, according to a statement on its website.
CME told investors in August it expects the deal for the UK trading and technology group to close by the end of the year. The deal also needs approval from the US Department of Justice, although there is no formal public filing in the US.
If approved, the combination will turn Chicago’s CME into the dominant market operator in the US$500 billion-a-day US Treasuries market, reported the Financial Times.
Full Content: Financial Times
Featured News
Federal Judge Signals Revisions Likely in DOJ Case Targeting Live Nation Monopoly
Jan 22, 2025 by
CPI
American Airlines and JetBlue Agree to $2 Million Legal Fee Settlement with U.S. States
Jan 22, 2025 by
CPI
Federal Judge Dismisses Class Action Alleging Inflated Yacht Commission Fees
Jan 22, 2025 by
CPI
Doug Gurr Appointed Interim Chairman of UK’s Competition Authority
Jan 22, 2025 by
CPI
LinkedIn Faces Lawsuit Over Alleged Misuse of Customer Data for AI Training
Jan 22, 2025 by
Amanda Adams
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan